M⁶A modification in cardiovascular disease: With a focus on programmed cell death

Area of Science:

• Epigenetics
• Molecular Biology
• Cardiovascular Research

Background:

• N6-methyladenosine (m6A) is a prevalent internal RNA modification in eukaryotes.
• Cardiovascular diseases (CVDs) are a leading global cause of mortality.
• Programmed cell death (PCD) is increasingly recognized for its role in CVD pathogenesis.

Purpose of the Study:

• To explore the intricate relationship between m6A modification mechanisms and PCD signaling pathways in CVDs.
• To elucidate the molecular mechanisms by which m6A modification influences PCD in the context of cardiovascular diseases.
• To identify potential therapeutic targets for CVDs based on m6A-mediated PCD regulation.

Main Methods:

• Review and synthesis of existing literature on m6A modification, PCD, and CVDs.
• Analysis of molecular signaling pathways involved in m6A regulation and programmed cell death.
• Exploration of the interplay between m6A machinery and cell death pathways in cardiovascular contexts.

Main Results:

• m6A modification is implicated in the development and progression of various diseases, including CVDs.
• Specific m6A regulators and their targets are associated with distinct PCD pathways relevant to cardiovascular health.
• The precise molecular mechanisms linking m6A to PCD in CVDs are complex and require further investigation.

Conclusions:

• Elucidating the connection between m6A mechanisms and PCD is crucial for understanding CVD pathogenesis.
• Targeting m6A-mediated PCD offers promising avenues for novel CVD prevention and therapeutic strategies.
• Further research into the clinical applications of m6A modulation in CVDs is warranted.